HCMHUTCHMED (China) Limited
Is it safe?
Caution warranted: heavy debt (BB) and big price swings.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -82% · now 16% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can HCM take a bad year?
HUTCHMED (China) Limited holds $190M more cash than debt, and is burning $22M a quarter, about 2.4 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 2.4 years
Cash runway · burning $22M a quarter at the current rate
- Annualised volatility
- 49%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ4 2019
- $27M
- Cash and short-term investments
- $217M
- Net cash
- $190M
- EBITDA, trailing twelve months
- −$141M
- Operating profit, trailing twelve months
- −$146M
- Debt / equity
- 0.09×
- Annualised volatilitytwo years of daily moves
- 49%
- Worst drawdown on file
- −82%
- Below its 52-week high
- 16%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #38 of 41 by RyuScore